Yamamoto A, Yokoyama S, Yamamura T
Department of Etiology and Pathophysiology, National Cardiovascular Center Research Institute, Osaka, Japan.
Atherosclerosis. 1988 Jun;71(2-3):257-60. doi: 10.1016/0021-9150(88)90150-5.
3 beta-Hydroxycompactin, a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is a useful drug as an anticholesterolemic agent. However, in some patients with familial hypercholesterolemia, treatment was associated with a rebound in serum cholesterol concentration when the dose was increased from 10 to 40 mg/day. The rebound was more remarkable when the basal cholesterol level was lowered by cholestyramine and/or probucol. The phenomenon seems to be due to an induction of HMG-CoA reductase as seen in some animals and cultured cells.